Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
Portfolio Pulse from Vandana Singh
Biogen and Denali Therapeutics are discontinuing a Phase 3 program for BIIB122, a Parkinson's disease treatment, amidst R&D restructure. The companies will now focus on the ongoing Phase 2b LUMA study in patients with early-stage Parkinson's.
June 05, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen discontinues Phase 3 program for BIIB122, a Parkinson's disease treatment, and focuses on Phase 2b LUMA study.
Biogen's decision to discontinue the Phase 3 program for BIIB122 may negatively impact its stock price in the short term, as it signals a change in the company's R&D priorities and potential delays in bringing the treatment to market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Denali Therapeutics' partnership with Biogen shifts focus from Phase 3 program for BIIB122 to Phase 2b LUMA study.
Denali's partnership with Biogen to develop BIIB122 is affected by the discontinuation of the Phase 3 program. This may negatively impact Denali's stock price in the short term, as it indicates a change in R&D priorities and potential delays in bringing the treatment to market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100